CML HealthCare Inc. to Install North America's First and World's Largest Fully Automated BD Kiestra Microbiology Platform

Mon Apr 8, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130408:nPnNY90047

Leading Canadian Laboratory Services Provider to Implement BD Kiestraâ„¢ Total
Laboratory Automation Platform by Third Quarter 2013
MISSISSAUGA, Ontario,  April 8, 2013  /PRNewswire/ -- CML HealthCare Inc. (TSX:
CLC) (the "Company" or "CML"), a leading community-based provider of laboratory
and medical imaging services in  Ontario  and  British Columbia, and BD (Becton,
Dickinson and Company) (NYSE: BDX), a leading global medical technology company,
today announced an agreement for CML to install two BD Kiestra Total Laboratory
Automation ("TLA") systems. This fully automated microbiology system will be
installed at CML's central laboratory by the third quarter of 2013. The BD
Kiestra TLA system is designed to significantly increase overall microbiology
lab productivity, streamline workflow, and shorten the time to results.  

"We are very excited to be the first laboratory services provider in  North
America  to be installing the BD Kiestra TLA system.  With our central
laboratory processing approximately three million microbiology tests annually,
this installation will be the largest in the world for the BD Kiestra TLA
system," said  Thomas Wellner, President and CEO of CML. "The implementation of
the BD Kiestra TLA system will allow CML to increase our capacity, reduce result
turnaround times, and contribute to the growth of our core laboratory business. 
It will provide us with a significant competitive advantage and support a key
pillar of our growth strategy which is to establish innovative hospital and
other partnerships."

BD Kiestra TLA system automates the manual processes associated with inoculating
and incubating microbiology specimens, and uses digital imaging of the
inoculated specimens to shorten the time to detect bacterial growth. The
increased efficiency, and quality improvements associated with automation allow
for faster delivery of more accurate results to provide optimal patient care. In
addition, laboratory staff is able to devote more time to analytical and
value-added tasks.

"BD is proud to be working with CML HealthCare Inc., one of  Canada's largest
and most forward-looking laboratory services providers," said  Tom Polen,
President, BD Diagnostics - Diagnostic Systems. "Rapid diagnosis and treatment
of infections is critical; however, many of the traditional testing protocols
take two or three days to generate an actionable result.  Using the BD Kiestra
TLA system, integrated with other rapid diagnostic technologies, CML will be a
pioneer in implementing technology that can often reduce those times
significantly.  We expect this to enable clinicians to provide patients with the
most effective treatment earlier - thus improving the standard of care and
avoiding unnecessary healthcare costs."  

The BD Kiestra TLA system currently has an installation base of instruments at
public hospitals, universities, and privately owned laboratories in more than
eleven countries worldwide since its introduction in 2006.

About CML HealthCare Inc.

Based in  Mississauga, Ontario, CML HealthCare Inc. is a leading
community-based, medical diagnostic services provider in  Canada  operating 114
Client C.A.R.E. Centres in  Ontario, 84 imaging centres in  Ontario  and 
British Columbia, and a reference laboratory in  Ontario  focused on specialized
coagulation testing and equipment calibration for international customers.  CML
is publicly-traded on the Toronto Stock Exchange under the symbol "CLC" and has
approximately 89.8million common shares outstanding. For more information,
please visit  www.cmlhealthcare.com  or follow CML on Twitter @cmlhealthcare.  

About BD

BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents. The Company is
dedicated to improving people's health throughout the world. BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in  Franklin Lakes, New Jersey, BD employs nearly 30,000
associates in more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please
visit  www.bd.com.

For more information, please contact:

 Alice Dunning, MBA, CFA             Jamie Yacco          
 Director, Corporate Communications  BD Public Relations  
 CML HealthCare Inc.                 (201) 847-4796       
 (905) 565-0043 ext. 3472            Jamie_Yacco@bd.com   
 (905) 565-2844 fax                                       
 DunningA@cml.ca                                          


SOURCE  BD-Becton Dickinson

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.